Zoliflodacin: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|April 19, 2026
Summary
Zoliflodacin is a new oral antibiotic approved for uncomplicated urogenital gonorrhea. This single-dose treatment offers a novel option for Neisseria gonorrhoeae infections in adults and adolescents.
Area of Science:
- Pharmacology and Infectious Diseases
- Bacteriology
- Drug Development
Background:
- Neisseria gonorrhoeae poses a significant public health threat due to rising antimicrobial resistance.
- Existing treatments for gonorrhea face challenges with resistance and administration.
- Development of novel antibiotics is crucial to combat resistant bacterial infections.
Purpose of the Study:
- To summarize the development milestones of zoliflodacin.
- To highlight the first approval of zoliflodacin for uncomplicated urogenital gonorrhea (uUGC).
- To provide an overview of this first-in-class antibiotic.
Main Methods:
- Review of preclinical and clinical development data for zoliflodacin.
- Analysis of regulatory submission and approval processes.
- Summary of key findings from pivotal trials.
Main Results:
- Zoliflodacin, a spiropyrimidinetrione, targets bacterial type II topoisomerase.
- The drug received US FDA approval in December 2025 for uUGC treatment.
- Approved for adults and pediatric patients (≥12 years, ≥35 kg) with Neisseria gonorrhoeae infection.
Conclusions:
- Zoliflodacin represents a significant advancement in gonorrhea treatment.
- The single-dose oral formulation offers a convenient therapeutic option.
- This approval marks a critical milestone in addressing drug-resistant gonorrhea.
More Related Videos
09:24Application and Methodology of the Non-destructive 19F Time-domain NMR Technique to Measure the Content in Fluorine-containing Drug Products
Published on: August 22, 2017
8.9K
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
15.8K
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
337
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
337
01:28Inhibitors of Bacterial DNA Synthesis
97
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
97
01:17Drugs for Treatment of Diarrhea-Predominant IBS
970
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
970
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832